Testing the external validity of the EORTC randomized trial 30904 comparing overall survival after radical nephrectomy vs nephron-sparing surgery in contemporary North American patients with renal cell cancer.

Authors

Firas Abdollah, Henry Ford HealthFollow
Sohrab Arora, Henry Ford HealthFollow
Nicolas von LandenbergFollow
Philipp Gild
Akshay Sood, Henry Ford HealthFollow
Deepansh Dalela, Henry Ford HealthFollow
Quoc-Dien Trinh
Mani Menon, Henry Ford HealthFollow
Craig G. Rogers, Henry Ford HealthFollow

Recommended Citation

Abdollah F, Arora S, von Landenberg N, Gild P, Sood A, Dalela D, Trinh QD, Menon M, and Rogers C. Testing the external validity of the European Organization for Research and Treatment of Cancer randomized trial 30904 comparing overall survival after radical nephrectomy vs nephron-sparing surgery in contemporary North American patients with renal cell cancer. BJU Int 2017; 121(3):345-347.

Document Type

Article

Publication Date

3-1-2018

Publication Title

BJU international

Medical Subject Headings

Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Middle Aged; Nephrectomy; North America; Organ Sparing Treatments; Patient Selection; Randomized Controlled Trials as Topic; Survival Rate

PubMed ID

28972695

Volume

121

Issue

3

First Page

345

Last Page

347